GE Healthcare
AI tools have impressive potential in personalizing treatments, but doctors are concerned about bias, generalizability, and the lack of prospective validation.
Wisconsin Consortium Seeks US Economic Development Administration Funding for Biohealth Projects
The consortium's six projects are part of the Wisconsin Biohealth Tech Hub, which aims to bolster personalized medicine in the state.
The researchers hope to reproduce in a prospective clinical trial the model's 70 percent to 80 percent accuracy for predicting immunotherapy response.
GE Healthcare Licenses Sofie Biosciences' FAP-Targeting Diagnostic Radiopharmaceuticals
GE gained worldwide rights to develop and commercialize Sofie's gallium 68-labeled PET imaging agent and ex-US rights to its fluorine 18-labeled PET imaging agent.
GE Healthcare Educating Docs on Guidelines-Backed Use of Imaging Agent for ER-Positive Breast Cancer
Premium
Cerianna, a radiolabeled imaging agent that reveals ER-positive breast cancers, is FDA approved as an adjunct to biopsy, but recent guidelines say it may have additional uses in certain circumstances.